Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Pretreatment with PKI-166 (0-0
placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
is a competitive inhibitor of the ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C)
isolated from Stemona tuberosa
m-PEG4-Br Size:Contact [email protected] for quotation Pretreatment with PKI-166 (0-0m PEG4 Br is a cleavable ADC linker used in the synthesis of antibody drug conjugate (ADC) for Trastuzumab (HY P9907). m PEG4 Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency. m PEG4 Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs. Product information CAS Number: 110429 45 3 Molecular Weight: 271. 15 Formula:
US$ 99.00
US$ 137.12
US$ 189.99
US$ 117.16
US$ 150.75
US$ 1249.64
US$ 147.50